文献速递免疫规划卫生政策与健康促进

成人15价和20价肺炎球菌疫苗成本效果分析的系统文献综述

Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.
PubMed 文献 · Vaccine · 2024-12-27

该系统综述检索截至2024年4月23日的多个数据库,纳入26项成人PCV15和/或PCV20的成本效果分析研究。多数研究(22/26)结论为PCV20单独使用相比其他成人肺炎球菌策略具有成本节约(优势)或成本效果。当前证据提示PCV20单独使用可能具有成本效果或优于其他策略,未来研究需解决假设中的不确定性。

要点

  • 26项纳入研究中24项涉及高收入国家,均采用静态马尔可夫模型。
  • 22/26项研究结论为PCV20单独使用相比其他策略具有成本节约(优势)或成本效果。
  • 13/26项研究纳入儿童高價疫苗群体效应、血清型替换或两者,减弱了成人疫苗影响。

核心结论

  • 当前证据提示,20价肺炎球菌结合疫苗单独使用可能具有成本效果或优于其他成人肺炎球菌策略。
  • 未来研究需解决假设中的剩余不确定性,以支持循证决策。

研究设计与样本

  • 系统文献综述,检索PubMed、EMBASE、CEA Registry、EconLit、HTA Database和NITAG资源中心截至2024年4月23日的成本效果分析研究。
  • 纳入26项评估成人PCV15和/或PCV20与现有策略比较的成本效果分析研究,由两名评价者独立提取资料,采用ECOBIAS评估质量。

主要发现

  • 共识别137条记录,纳入26项研究;多数(24/26)涉及高收入国家。
  • 所有研究均采用静态马尔可夫模型,比较高價PCV单独使用或与PPSV23联合使用与当前推荐策略(单独PPSV23、单独PCV13、PCV13+PPSV23、不接种)。
  • 多数研究(22/26)结论为PCV20单独使用相比其他成人肺炎球菌策略(单独PPSV23、PCV13±PPSV23、PCV15±PPSV23或不接种)具有成本节约(优势)或成本效果。
  • PCV通常被假设具有与关键试验中PCV13效力相等的血清型特异性效力,但四项研究使用Delphi小组的估计值;保护持续时间假设为10至20年。
  • PPSV23被假设对非菌血症性肺炎效力较低且保护持续时间较短;半数研究(13/26)纳入儿童高價PCV群体效应(12/26)、血清型替换(2/26)或两者(1/26),减弱了成人疫苗影响。

关键数值与推荐

  • 多数研究评估为低偏倚风险;五项摘要未提供足够信息进行评估。
  • PCV保护持续时间假设为10至20年。

局限性

  • 多数研究(24/26)涉及高收入国家。
  • 五项摘要未提供足够信息进行偏倚风险评估。
  • 未来研究需解决假设中的剩余不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The economic and public health benefits of adult pneumococcal vaccines vary across countries due to different epidemiology and costs. We systematically reviewed and summarized findings and assumptions of cost-effectiveness analyses (CEA) of the recently introduced 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) in adults. METHODS: We performed a systematic search for CEA studies of PCV15 and/or PCV20 versus existing strategies via PubMed, EMBASE, CEA Registry, EconLit, HTA Database, and NITAG resource center through April 23, 2024. Study characteristics, methods, assumptions, and findings were extracted independently by two reviewers; quality was assessed using ECOBIAS. Results were synthesized qualitatively to summarize key attributes and conclusions. RESULTS: Of 137 identified records, 26 studies were included; the majority (24/26) concerned high-income countries. All employed static Markov-type models comparing higher-valent PCVs used alone or in combination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) to current recommendations (PPSV23 alone, PCV13 alone, PCV13 + PPSV23, no vaccination). Most studies (22/26) concluded PCV20 used alone was cost-saving (dominant) or cost-effective compared to other adult pneumococcal strategies (PPSV23 alone, PCV13 ± PPSV23, PCV15 ± PPSV23, or no vaccination). PCVs were generally assumed to have serotype-specific effectiveness equal to PCV13 efficacy in the pivotal trial, though four studies used estimates from a Delphi panel; protection was assumed to last between 10 and 20 years. PPSV23 was assumed to have lower effectiveness against non-bacteremic pneumonia and shorter duration of protection. Herd effects from higher-valent PCVs in childhood (12/26), serotype replacement (2/26), or both (1/26) were included in half (13/26) of studies, which attenuated adult vaccine impact. Most studies were assessed as low risk of bias; five abstracts did not provide sufficient information for assessment. CONCLUSION: Current evidence indicates that 20-valent PCV used alone is likely to be cost-effective or dominate other adult pneumococcal strategies. Future research is needed to address remaining uncertainties in assumptions and to support evidence-based policymaking.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cho JY, Lee H, Wannaadisai W, et al. Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines. Vaccine. 2024. PMID: 39731806. doi:10.1016/j.vaccine.2024.126656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。